Written in English
|The Physical Object|
|Number of Pages||119|
Conjugates of Desferrioxamine B (DFOB) with Derivatives of Adamantane or with Orally Available Chelators as Potential Agents for Treating Iron Overload. Journal of Medicinal Chemistry , 53 (3), DOI: /jmCited by: Chelating agents for the treatment of systemic iron overload. Curr. Med. Chem. 19(17), – ().Crossref, Medline, CAS, Google Scholar; 5 Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood (9), – ( Cited by: 1. Deferasirox (DEF) is a bis-hydroxy-triazole tridentate iron chelator that is strongly chelating iron ions, non-toxic, and highly clinic, deferasirox was used to reduce the iron overload caused by blood r, there was no effect on reducing iron ion content in the sirox smoothly passes through the blood-brain barrier following binding to by: 4. Iron chelation therapy is used when you have a condition called iron overload means you have too much iron in your body. This can be a problem for people who get lots of red blood cell transfusions. Since red blood cells contain iron, each time you get a red blood cell transfusion you are putting more iron in your body. Your body has no good way to get rid of the extra iron.
In this autosomal recessive disorder, the iron overload is the result of an abnormality affecting the regulation of iron absorption that produces an inappropriate increase in iron uptake, with homozygotes developing a chronic progressive increase in body iron stores A candidate gene for this disorder has been recently identified Minor. An exceptionally stable complex [FeL2]3− is formed from the ligand H3L and FeIII. In contrast, the affinity of this ligand for other biometals is relatively small. These properties make H3L a hig. divalent metals such as calcium. Iron complexation behavior of these solution phase chelating compounds has been studied by UV-Vis spectrophotometric methods. These hydroxamate chelators have potential applications as chelating agents in the treatment of iron and aluminum overload. The clinical assessment of DFP as a potential iron redeployment agent has been facilitated by (i) the drug's good safety profile in the treatment of hemosiderosis (Berdoukas et al., ) (ii) its proven chelating (and thus life-saving) effect in patients with severe cardiac siderosis (Wood, ; Berdoukas et al., ; Pennell et al.,
Pitt CB, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Sprinkle Hardy KA, Whitcomb DR, Byers BR, Arceneaux JEL, Gaines CG, Sciortino CV () The selection and evaluation of new chelating agents for the treatment of iron overload. • Iron overload was present in 28 % of men and 1 % of women at age • Iron overload with CY/H63D is rare without other risk factors such as liver disease • CY homozygosity doubles the colon cancer risk in everyone and the breast cancer risk in women’ • H63D homozygosity triples the hereditary nonpolyposis colon cancer risk. chelating agents can be designed which scavange non-protein bound forms of these metals, thereby minimising undesirable hydroxyl radical formation. Such compounds are currently being investigated for the treatment of ischaemic damage associated with both stroke and heart attack. Iron chelating agents also have potential as. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease. Journal of Laboratory and Clinical Medicine , (4), .